Latest News

Cellectricon launches outsourced Discovery Services to enhance research into cytoskeletal disturbances

Mölndal, Sweden, April. 4, 2013

Cellectricon today announced the launch of its Discovery Services division. The new services offer pharma/biotech companies and CROs cutting-edge phenotypic screening support, accelerating drug discovery and cell-based assay research into cytoskeletal disturbances – especially for chronic pain.

Cellectricon’s Discovery Services aim to help drug discovery teams shorten lead development times and reduce costs. With leading expertize in assay development and screening, Cellectricon’s Discovery Services team provides fully collaborative support, tailored to each individual study. The entire services process is highly interactive, and guarantees all partners are well informed via frequent reports on assay performance, observations and progress, to ensure project goals are fully realized.

Announcing the new offering, Dr Paul Karila, Head of Cellectricon’s Discovery Services, said: “Our Cellaxess Elektra discovery platform is ideal for compound profiling in excitable primary cells and native tissue using transfection and specific electric field stimulation (EFS). With our platform, we can help researchers identify phenotypic effects in highly relevant biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.”

For more information on Cellectricon’s Discovery Services and how the new services can benefit your research, visit www.cellectricon.com/discovery-services